In a nutshell This clinical trial evaluated the survival benefits of a drug named Enzalutamide (Xtandi) for patients with non-responsive (refractory) advanced prostate cancer previously treated with chemotherapy. Main findings: Enzalutamide prolonged survival by approximately 5 months and reduced the risk of death by 37%. Some background The...
Read MoreExperimental drug – Enzalutamide – moderately increases survival in patients with advanced prostate cancer
